Bioxcel Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
BioXcel Therapeutics reported increased product revenue but a wider net loss in Q1 2026, with ongoing concerns about its ability to continue as a going concern.
NASDAQ
BioXcel Therapeutics, Inc. reported increased net losses and decreased product revenue for Q3 2025, while achieving positive safety and exploratory efficacy results in its SERENITY At-Home Phase 3 trial for agitation.
NASDAQ
BioXcel Therapeutics reports substantial losses and declining product revenue, raising significant doubt about its ability to continue as a going concern, despite progress in clinical trials and recent capital raises.
NASDAQ
10-Q: BioXcel Therapeutics Reports Q1 2025 Financial Results, Highlights SERENITY At-Home Trial Enrollment
BioXcel Therapeutics announces its Q1 2025 financial results, emphasizing the full enrollment of the SERENITY At-Home trial and providing updates on its clinical programs.
NASDAQ
BioXcel Therapeutics announced its Q3 2024 results, highlighting a strategic shift towards BXCL501 clinical development and further workforce reductions to extend its cash runway.
NASDAQ
BioXcel Therapeutics reports second quarter 2024 results, highlighting a strategic shift towards core clinical programs and a reduction in operating expenses.
NASDAQ
BioXcel Therapeutics reported its first quarter 2024 financial results, highlighting a strategic shift towards at-home treatments and advancements in its clinical programs.